Atom Bioscience raises $83M in Series D for URAT1 inhibitorURAT1 inhibitor in chronic gout treatment
16 Oct 2023
Phase 2Phase 1PROTACs
Atom Bioscience has pulled in $83 million in Series D financing for its URAT1 inhibitorURAT1 inhibitor for chronic gout, the company announced Monday, with the money going toward finishing its pivotal trials for the drug.
The Chinese company has raised $165 million total over its financing rounds, thanks to investors like Kaitai Capital, Fortune Capital, Huajin Investment, Unifortune and NNFE Investment.
Atom touted ABP-671’s ability to reduce serum uric acid levels in urine by inhibiting URAT1, the primary endpoint in trials. Chronic gout is caused by elevated levels of the acid, also known as hyperuricemia.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.